Loss of expression of the p16(INK4)/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage

International Journal of Cancer

Volumn 74, Issue 3, 1997, Pages 255-259

  Talve, L ^a   Sauroja, I ^b   Collan, Y ^a   Punnonen, K ^a   Ekfors, T ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA REPLICATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTIC NEVUS; MELANOMA; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; ADULT; AGED; CELL DIVISION; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

CARRIER PROTEIN; KI 67 ANTIGEN; PROTEIN P16INK4A; TUMOR PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 0030610586     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y     Document Type: Article

References (36)

1. ARAP, W., NISHIKAWA, R., FURNARI, F.B., CAVENEE, W.K. and HUANG, H.-J.S., Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res., 55, 1351-1354 (1995).
2. CAIRNS, P. and 20 OTHERS, Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nature (Genet.), 11, 210-212 (1995).
3. COLLAN, Y., General principles of grading lesions in diagnostic histopathology. Pathol. Res. Pract., 185, 539-543 (1989).
4. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55, 6006-6011 (1995).
5. INK4A expression in human breast cancer. Amer. J. Pathol., 149, 15-20 (1996).
6. GRANA, X. and REDDY, E.P., Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211-219 (1995).
7. CDKN2 expression and its implications for cell immortalization and senescence. Mol. cell. Biol., 16, 859-867 (1996).
8. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A.T., ALLY, D.S., SHEAHAN, M.D., CLARK, W.H., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature (Genet.), 8, 15-21 (1994).
9. INK4 gene mediated by an adenovirus vector. Cancer Res., 55, 3250-3253 (1995).
10. KAMB, A. and 23 OTHERS, Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature (Genet.). 8, 22-26 (1994).
11. KOH, J., ENDERS, G.H., DYNLACHT, B.D. and HARLOW, E., Tumor derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375, 506-510 (1995).
12. LI, Y.-J., HOANG-XUAN, K., DELATTRE, J.-Y., POISSON, M., THOMAS, G. and HAMELIN, R., Frequent loss of heterozygosity on chromosome 9. and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene, 11, 597-600 (1995).
13. LILISCHKIS, R., SARCEVIC, B., KENNEDY, C., WARLTERS, A. and SUTHERLAND, R., Cancer-associated mis-sense and deletion mutations impair p16/INK4 CDK inhibitory activity. Int. J. Cancer, 66, 249-254 (1996).
14. INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene, 11, 405-112 (1995).
15. LIU, Q., NEUHAUSEN, S., MCCLURE, M., FRYE, C., WEAVER-FELDHAUS, J., GRUIS, N.A., EDDINGTON, K., ALLANUIS-TURNER, M.J., SKOLNICK, M.H., FUJIMURA, F.K. and KAMB, A., CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067 (1995).
16. Lo, K.-W., HUANG, D.P. and LAU, K.-M., p16 gene alteration in nasopharyngeal carcinoma. Cancer Res., 55, 2039-2043 (1995).
17. LOIS, A.F., COOPER, L.T., GENG, Y., NOBORI, T. and CARSON, D., Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. Cancer Res., 55, 4010-4013 (1995).
18. LUKAS, J., PARRY, D., AAGAARD, L., MANN, D.J., BARTKOVA, J., STRAUSS, M., PETERS, G. and BARTEK, J., Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375, 503-506 (1995).
19. NAGAKAWA, K., CONRAD, N.K., WILLIAMS, J.P., JOHNSON, B.E. and KELLEY, M.J., Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene, 11, 1843-1851 (1995).
20. INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
21. POLLOCK, P.M., YU, F., QIU, L., PARSONS, P.G. and HAYWARD, N.K., Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11, 663-668 (1995).
22. INK4 function. Nature (Genet.), 10, 114-116 (1995).
23. REED, J.A., LOGANZO, F., SHEA, C.R., WALKER, G.J., FLORES, J.F., GLENDENING, J.M., BOGDANY, J.K., SHIEL, M.J., HALLUSKA, F.G., FOUNTAIN, J.W. and ALBINO, A.P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55, 2713-2718 (1995).
24. REYMOND, A. and BRENT, R., p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene, 11, 1173-1178 (1995).
25. SAENZ-SANTAMARIA, M.C., MCNUTT, N.S. and SHEA, C.R., Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Brit. J. Dermatol., 133, 890-895 (1995).
26. INK4A as a human tumor suppressor. Biochim. biophys. Acta, 1242, 165-169 (1996).
27. 1 cyclin-dependent kinases. Genes Develop., 9, 1149-1163 (1995).
28. INK4A) somatic and germline mutations. Hum. Mutation, 7, 294-303 (1996).
29. SONODA, Y., YOSHIMOTO, T. and SEKIYA, T., Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene, 11, 2145-2149 (1995).
30. SOUCEK, T., PUSCH, O., HENGSTSCHÄGER-OTTNAD, E., WAWRA, E., BERNASCHEK, G. and HENGSTSCHÄGER, M., Expression of the cyclin-dependent kinase inhibitor p16 during the ongoing cell cycle. FEBS Lett., 373, 164-169 (1995).
31. SVANHOLM, H., STARKLINT, H., GUNDERSEN, H.J.G., FABRICIUS, J., BARLEBO, H. and OLSEN, S., Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. Acta pathol. microbiol. immunol. Scand., 97, 689-698 (1989).
32. ink4. Cancer Res., 54, 5816-5814 (1994).
33. UEKI, K., ONO, Y., HENSON, J.W., EFIRD, J.T., VON DEIMLING, A. and LOUIS, D.N., CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56, 150-153 (1996).
34. WASHIMI, O., NAGATAKE, M., OSADA, H., UEDA, R., KOSHOKAWA, T., SEKI, T., TOSHITADA, T. and TAKAHASHI, T., In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55, 514-517 (1995).
35. WEISS, J., HEINE, M., ARDEN, K.C., KORNER, B., PILCH, H., HERBST, R.A. and JUNG, E.G., Mutation and expression of TP53 in malignant melanomas. Rec. Res. Cancer Res., 139, 137-154 (1995).
36. XIAO, S., LI, D., VIJG, J., SUGARBAKER, D.J., CORSON, J.M. and FLETCHER, J.A., Co-deletion of p15 and p16 in primary malignant mesothelioma. Oncogene, 11, 511-515 (1995).